Format

Send to:

Choose Destination
See comment in PubMed Commons below
Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):459-74, xi. doi: 10.1016/j.chc.2007.11.010.

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.

Author information

  • 1Child and Adolescent Treatment and Preventive Intervention Research Branch, Division of Services and Intervention Research, National Institute of Mental Health, Room 7147, 6001 Executive Boulevard, Bethesda, MD 20892-9633, USA. bvitiell@mail.nih.gov

Abstract

The effects of stimulant medications and atomoxetine on physical growth and on cardiovascular function are reviewed in light of the most recent data, with attention to clinical implications and research needs. Although these medications have a favorable benefit/risk profile and do not induce clinically significant changes in growth or cardiovascular function in the majority of cases, careful patient monitoring is needed to identify individuals at risk for negative outcomes. More research is needed to elucidate the mechanism of growth suppression to estimate better the risk for rare but life-threatening events and test the effectiveness of monitoring procedures.

PMID:
18295156
[PubMed - indexed for MEDLINE]
PMCID:
PMC2408826
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk